Pancreatic Cancer
Conditions
Keywords
stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, adenocarcinoma of the pancreas
Brief summary
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer that has been surgically removed.
Detailed description
Objective: I. Perform a pilot study of active immunotherapy with autologous dendritic cells pulsed with the CEA peptide, CAP-1, after surgical resection in patients with CEA expressing pancreatic cancer. II. Perform laboratory analysis to monitor the presence, persistence, and function of CAP-1 specific T-cells in this patient population. Outline: Patients undergo leukapheresis for up to 4.5 hours prior to vaccination. Half of the collected dendritic cells are pulsed with carcinoembryonic antigen (CEA) peptide and the other half are pulsed with hepatitis B antigen peptide (HBsAg). Equal doses of CEA and HBsAg peptide pulsed dendritic cells are administered intravenously over 3 minutes every 4 weeks for a total of 6 doses each. Patients undergo a second leukopheresis 2 weeks after the last dose of immunotherapy to obtain specimens for immunologic tests. Patients are followed at weeks 22, 36, 48, and every 6 months thereafter. Project Accrual: A total of 24 patients will be accrued for this study over 2 years.
Interventions
BIOLOGICALhepatitis B antigen peptide
BIOLOGICALcarcinoembryonic antigen peptide 1
Sponsors
National Cancer Institute (NCI)
Duke University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Disease Characteristics: * Histologically confirmed stage I, II, or III adenocarcinoma of the pancreas Resected with no gross residual disease At least 50% of tumor cells must be CEA positive and stain with at least moderate intensity HLA-A2 positive Patient Characteristics: * Age: 18 and over * Performance status: Karnofsky 70-100% * Life expectancy: Greater than 6 months * Hematopoietic: Absolute neutrophil count at least 1000/mm3 * Hepatic: Bilirubin less than 2.0 mg/dL SGOT and alkaline phosphatase less than 4 times the upper limit of normal No hepatic failure * Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min * Cardiovascular: No New York Heart Association class III or IV heart disease * Pulmonary: No concurrent asthma or chronic obstructive pulmonary disease Other: * No other malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years. * No history of autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis, or multiple sclerosis * No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis * No active infectious enteritis or eosinophilic enteritis Not pregnant or nursing Fertile patients must use effective contraception Prior Therapy: * Biologic therapy: At least 4 weeks since immunotherapy. No other concurrent immunotherapy * Chemotherapy: At least 4 weeks since chemotherapy and recovered. No concurrent chemotherapy * Endocrine therapy: No concurrent corticosteroid or immunosuppressive therapy. At least 6 weeks since steroid therapy * Radiotherapy: At least 4 weeks since radiotherapy and recovered * Surgery: Recovered from prior surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival | — |
Countries
United States
Outcome results
None listed